海科新源(301292.SZ):全資子公司動力電池高端材料及配套項目試生產
格隆匯8月7日丨海科新源(301292.SZ)公佈,近日,山東海科新源材料科技股份有限公司收到東營港經濟技術開發區應急管理局下發的《危險化學品建設項目試生產(使用)方案備案吿知書》(東港開危化項目備字〔2025〕07號)。東營港經濟技術開發區應急管理局同意公司全資子公司山東新蔚源新材料有限公司“動力電池高端材料及配套項目”的試生產方案,試生產(使用)期限為2025年8月6日至2026年8月5日。山東新蔚源新材料有限公司後續將嚴格按照法律法規的要求及產品生產工序、流程有序安排試生產工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.